Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

American Heart Journal

Volumn 151, Issue 2, 2006, Pages 373-379

  Fitchett, David H ^a   Langer, Anatoly ^a   Armstrong, Paul W ^b   Tan, Mary ^a   Mendelsohn, Aurora ^a   Goodman, Shaun G ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGINA, UNSTABLE; ANTICOAGULANTS; ASPIRIN; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME;

EID: 31344472944     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.05.003     Document Type: Article

References (15)

1. M. Cohen, C. Demers, and E. Gurfinkel A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary disease N Engl J Med 337 1997 447 452
2. E.M. Antman, C.H. McCabe, and E. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction TIMI 11B trial Circulation 100 1999 1593 1601
3. E.M. Antman, M. Cohen, and C.H. McCabe Enoxaparin is superior to unfractionated heparin for preventing clinical events at one year follow-up of TIMI 11B and ESSENCE Eur Heart J 23 2002 308 314
4. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Treatment benefit of enoxaparin in unstable angina/non-Q wave myocardial infarction is maintained at one year followup in TIMI 11B Circulation 100 1999 I 497
5. M. Cohen, C. Demers, and E.P. Gurfinkel Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events Am J Cardiol 82 1998 19L 24L
6. S.G. Goodman, D.H. Fitchett, and P. Armstrong Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high risk patients with non ST segment elevation acute coronary syndromes receiving the GP IIb/IIIa receptor inhibitor eptifibatide Circulation 107 2003 238 244
7. J.I. Weitz Low-molecular-weight heparins N Engl J Med 337 1997 698
8. FRISC Study Group Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group [see comments] Lancet 347 1996 561 568
9. E.M. Antman, M. Cohen, and D. Radley Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis Circulation 100 1999 1602 1608
10. S.G. Goodman, M. Cohen, and F. Bigonzi Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. One-year results of the ESSENCE study J Am Coll Cardiol 36 2000 693 698
11. M. Cohen, P. Theroux, and M.J. Frey Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study Circulation 102 2000 II 826
12. The Synergy Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
13. M.A. Blazing, J. deLemos, and H.D. White Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST segment acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial JAMA 292 2004 55 64
14. J.A. De Lemos, M.S. Blazing, and S.D. Wiviott Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-t_Z trial Eur Heart Js 25 2004 1688 1694
15. J.L. Petersen, K.W. Mahaffey, and V. Hasselblad Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for anti-thrombin therapy in non-ST segment elevation acute coronary syndromes JAMA 292 2004 89 96